INCY

SEC source: 0001628280-25-031013 · wk-form4_1749760237.xml · derivative · entry 2

FOUSE JACQUALYN A · CIK 0001405288 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,216

Underlying: Common Stock · 9,216 shares

Expires 2035-06-09

F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

SEC source: 0001628280-25-031013 · wk-form4_1749760237.xml · nonDerivative · entry 1

FOUSE JACQUALYN A · CIK 0001405288 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,326

F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001628280-25-031007 · wk-form4_1749760172.xml · derivative · entry 2

High Katherine A · CIK 0001631248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,216

Underlying: Common Stock · 9,216 shares

Expires 2035-06-09

F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

SEC source: 0001628280-25-031007 · wk-form4_1749760172.xml · nonDerivative · entry 1

High Katherine A · CIK 0001631248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,341

F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000950170-25-085458 · ownership.xml · derivative · entry 7

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,216

Underlying: Common Stock · 9,216 shares

Expires 2035-06-09

F13 · shares: Includes 9,216 Stock Options granted by the Issuer to Julian C. Baker on June 10, 2025, pursuant to the Incentive Plan. The Stock Options have a strike price of $70.07 and vest on the earlier of June 10, 2026, the date of the next annual meeting of stockholders of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the Board through the vesting date. The Stock Options expire on June 9, 2035.

F13 · derivative.exercise_date: Includes 9,216 Stock Options granted by the Issuer to Julian C. Baker on June 10, 2025, pursuant to the Incentive Plan. The Stock Options have a strike price of $70.07 and vest on the earlier of June 10, 2026, the date of the next annual meeting of stockholders of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the Board through the vesting date. The Stock Options expire on June 9, 2035.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to Julian C. Baker of 2,518 RSUs on Table I and 9,216 Stock Options on Table II. These grants of 2,518 RSUs and 9,216 Stock Options for Julian C. Baker are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-085458 · ownership.xml · derivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,216

Underlying: Common Stock · 9,216 shares

Expires 2035-06-09

F13 · shares: Includes 9,216 Stock Options granted by the Issuer to Julian C. Baker on June 10, 2025, pursuant to the Incentive Plan. The Stock Options have a strike price of $70.07 and vest on the earlier of June 10, 2026, the date of the next annual meeting of stockholders of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the Board through the vesting date. The Stock Options expire on June 9, 2035.

F13 · derivative.exercise_date: Includes 9,216 Stock Options granted by the Issuer to Julian C. Baker on June 10, 2025, pursuant to the Incentive Plan. The Stock Options have a strike price of $70.07 and vest on the earlier of June 10, 2026, the date of the next annual meeting of stockholders of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the Board through the vesting date. The Stock Options expire on June 9, 2035.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the non-qualified options to purchase Common Stock of the Issuer ("Stock Options") reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to Julian C. Baker of 2,518 RSUs on Table I and 9,216 Stock Options on Table II. These grants of 2,518 RSUs and 9,216 Stock Options for Julian C. Baker are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0000950170-25-085458 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 28,187,089

F1 · shares: Includes 2,518 restricted stock units (each an "RSU") payable solely in common stock ("Common Stock") of Incyte Corporation (the "Issuer") granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), on June 10, 2025, pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Incentive Plan"). The RSUs fully vest on the earlier of June 10, 2026, the date of the next annual meeting of stockholders of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Julian C. Baker serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 13,476 shares of Common Stock previously issued to Julian C. Baker pursuant to the Incentive Plan in lieu of director retainer fees, 12,204 shares of Common Stock received previously from vested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, each of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to Julian C. Baker of 2,518 RSUs on Table I and 9,216 Stock Options on Table II. These grants of 2,518 RSUs and 9,216 Stock Options for Julian C. Baker are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-085458 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,816,410

F1 · shares: Includes 2,518 restricted stock units (each an "RSU") payable solely in common stock ("Common Stock") of Incyte Corporation (the "Issuer") granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), on June 10, 2025, pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Incentive Plan"). The RSUs fully vest on the earlier of June 10, 2026, the date of the next annual meeting of stockholders of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Julian C. Baker serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the non-qualified options to purchase Common Stock of the Issuer ("Stock Options") reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 13,476 shares of Common Stock previously issued to Julian C. Baker pursuant to the Incentive Plan in lieu of director retainer fees, 12,204 shares of Common Stock received previously from vested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, each of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to Julian C. Baker of 2,518 RSUs on Table I and 9,216 Stock Options on Table II. These grants of 2,518 RSUs and 9,216 Stock Options for Julian C. Baker are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0001628280-25-031006 · wk-form4_1749760138.xml · derivative · entry 2

Clancy Paul J · CIK 0001409601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,216

Underlying: Common Stock · 9,216 shares

Expires 2035-06-09

F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

SEC source: 0001628280-25-031006 · wk-form4_1749760138.xml · nonDerivative · entry 1

Clancy Paul J · CIK 0001409601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,589

F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001628280-25-031001 · wk-form4_1749760105.xml · derivative · entry 3

Schaffert Susanne · CIK 0001938363 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,216

Underlying: Common Stock · 9,216 shares

Expires 2035-06-09

F4 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

SEC source: 0001628280-25-031001 · wk-form4_1749760105.xml · nonDerivative · entry 2

Schaffert Susanne · CIK 0001938363 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,389

F2 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F3 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001628280-25-031001 · wk-form4_1749760105.xml · nonDerivative · entry 1

Schaffert Susanne · CIK 0001938363 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,871

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

SEC source: 0001628280-25-030999 · wk-form4_1749760072.xml · derivative · entry 2

HARRIGAN EDMUND · CIK 0001177917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,216

Underlying: Common Stock · 9,216 shares

Expires 2035-06-09

F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

SEC source: 0001628280-25-030999 · wk-form4_1749760072.xml · nonDerivative · entry 1

HARRIGAN EDMUND · CIK 0001177917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,952

F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001628280-25-029631 · wk-form4_1749153646.xml · derivative · entry 3

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,757

Underlying: Common Stock · 1,795 shares

Expires 2033-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Beginning October 2, 2023, options become exercisable in 37 installments, with the first 25% vesting on October 2, 2024 and the remainder vesting monthly over three years.

SEC source: 0001628280-25-029631 · wk-form4_1749153646.xml · nonDerivative · entry 2

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,504

F1 · balance_after: This includes an aggregate of 25,848 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.

SEC source: 0001628280-25-029631 · wk-form4_1749153646.xml · nonDerivative · entry 1

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,299

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-25-029011 · wk-form4_1748980843.xml · nonDerivative · entry 2

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,003

F1 · balance_after: This includes an aggregate of 15,406 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001628280-25-029011 · wk-form4_1748980843.xml · nonDerivative · entry 1

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,654

SEC source: 0001628280-25-016582 · wk-form4_1743713556.xml · nonDerivative · entry 2

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,702

F2 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on the third anniversary of the July 2, 2022 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2022 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

F3 · balance_after: This includes an aggregate of 59,689 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0001628280-25-016582 · wk-form4_1743713556.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,726

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. While Dr. Flannelly will retire from the Company on July 31, 2025, the earned shares will vest on November 30, 2025 in line with the retirement provisions of the plan. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, achievement of specified Opzelura performance goals. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

SEC source: 0001628280-25-016581 · wk-form4_1743713528.xml · nonDerivative · entry 2

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,799

F2 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on the third anniversary of the July 2, 2022 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2022 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

F3 · balance_after: Includes an aggregate of 50,339 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0001628280-25-016581 · wk-form4_1743713528.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,817

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on November 30, 2025, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, achievement of specified Opzelura performance goals. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

SEC source: 0001628280-25-016579 · wk-form4_1743713452.xml · nonDerivative · entry 2

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,093

F2 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on the third anniversary of the July 2, 2022 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2022 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

F3 · balance_after: This includes an aggregate of 84,321 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0001628280-25-016579 · wk-form4_1743713452.xml · nonDerivative · entry 1

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,123

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on November 30, 2025, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, achievement of specified Opzelura performance goals. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

SEC source: 0001628280-25-016580 · wk-form4_1743713479.xml · nonDerivative · entry 1

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,164

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on November 30, 2025, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, achievement of specified Opzelura performance goals. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

F2 · balance_after: Includes an aggregate of 32,156 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0001628280-25-016576 · wk-form4_1743713415.xml · nonDerivative · entry 2

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,132

F2 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on the third anniversary of the July 2, 2022 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2022 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

F3 · balance_after: This includes an aggregate of 122,573 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.

SEC source: 0001628280-25-016576 · wk-form4_1743713415.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,165

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on November 30, 2025, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, achievement of specified Opzelura performance goals. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

SEC source: 0001628280-25-016572 · wk-form4_1743713388.xml · nonDerivative · entry 2

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,344

F2 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on the third anniversary of the July 2, 2022 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2022 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

F3 · balance_after: This includes an aggregate of 49,466 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0001628280-25-016572 · wk-form4_1743713388.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,362

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on November 30, 2025, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, achievement of specified Opzelura performance goals. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

SEC source: 0001628280-25-016570 · wk-form4_1743713353.xml · nonDerivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 563,573

F1 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on the third anniversary of the July 2, 2022 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2022 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

F2 · balance_after: This includes an aggregate of 181,595 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000950170-25-049436 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 28,184,571

F1 · shares: Includes 487 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $33,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 12,989 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 2,830 shares of Common Stock underlying unvested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 487 RSUs on Table I. The 487 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-049436 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,813,892

F1 · shares: Includes 487 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $33,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 12,989 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 2,830 shares of Common Stock underlying unvested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 487 RSUs on Table I. The 487 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0001628280-25-016172 · wk-form4_1743624374.xml · nonDerivative · entry 1

Clancy Paul J · CIK 0001409601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,071

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001628280-25-016170 · wk-form4_1743624329.xml · nonDerivative · entry 1

HARRIGAN EDMUND · CIK 0001177917 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,434

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001628280-25-015196 · wk-form4_1743109504.xml · nonDerivative · entry 1

Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,937

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 8,517 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001628280-25-013444 · wk-form4_1742328060.xml · nonDerivative · entry 3

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,567

F1 · balance_after: This includes an aggregate of 33,554 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0001628280-25-013444 · wk-form4_1742328060.xml · nonDerivative · entry 2

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,714

SEC source: 0001628280-25-013444 · wk-form4_1742328060.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,913

SEC source: 0001628280-25-010973 · wk-form4_1741298192.xml · derivative · entry 3

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,552

Underlying: Common Stock · 599 shares

Expires 2033-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Beginning October 2, 2023, options become exercisable in 37 installments, with the first 25% vesting on October 2, 2024 and the remainder vesting monthly over three years.

SEC source: 0001628280-25-010973 · wk-form4_1741298192.xml · nonDerivative · entry 2

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,848

F1 · balance_after: This includes an aggregate of 25,848 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.

SEC source: 0001628280-25-010973 · wk-form4_1741298192.xml · nonDerivative · entry 1

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,447

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-25-019280 · tm257996-1_4seq1.xml · derivative · entry 4

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,151

Underlying: Common Stock · 9,574 shares

Expires 2033-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Beginning October 2, 2023, options become exercisable in 37 installments, with the first 25% vesting on October 2, 2024 and the remainder vesting monthly over three years.

SEC source: 0001104659-25-019280 · tm257996-1_4seq1.xml · nonDerivative · entry 3

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,848

F1 · balance_after: This includes an aggregate of 25,848 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.

SEC source: 0001104659-25-019280 · tm257996-1_4seq1.xml · nonDerivative · entry 2

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,343

SEC source: 0001104659-25-019280 · tm257996-1_4seq1.xml · nonDerivative · entry 1

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,917

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000879169-25-000045 · wk-form4_1738618380.xml · nonDerivative · entry 1

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,515

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the January 31, 2025 grant, this includes an aggregate of 27,507 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-25-000044 · wk-form4_1738618351.xml · nonDerivative · entry 1

Heeson Lee · CIK 0002039219 · EVP, Head of Incyte Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,778

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the January 31, 2025 grant, this includes an aggregate of 32,778 shares of common stock issuable pursuant to previously reported RSUs that have not vested.

SEC source: 0000879169-25-000032 · wk-form4_1737579939.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,967

F1 · balance_after: This includes an aggregate of 64,408 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.